S&P Futures
4,273.75 -12.75 (-0.30%) Dow Futures
33,913.00 -68.00 (-0.20%) Nasdaq Futures
13,475.50 -47.75 (-0.35%) Russell 2000 Futures
1,993.20 -8.50 (-0.42%) Crude Oil
89.88 -0.62 (-0.69%) Gold
1,769.10 -2.10 (-0.12%)
Adastra Holdings Ltd. (XTRX.CN)
Chart Events
Performance Outlook
| Previous Close | 0.6200 |
| Open | 0.0000 |
| Bid | 0.6500 x N/A |
| Ask | 0.6700 x N/A |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 4,096 |
| Market Cap | 40.826M |
| Beta (5Y Monthly) | -0.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0210 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Adastra Expands Market Footprint Through Receipt of Medical Sales License from Health Canada
Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP)("Adastra" or the "Company"), a leading cannabis company focused on processing, product development, sales, organoleptic testing and analytical testing, is pleased to announce it has received its Medical Sales License from Health Canada which now authorizes Adastra to sell cannabinoid-containing products that are formulated for and distributed to the medical cannabis market.
- CNW Group
Adastra Holdings Continues to Execute on Transformational Strategy; New Product Launches; Outlines Growth Strategy
Adastra Holdings Ltd. (CSE: XTRX) (FRA: D2EP) ("Adastra" or the "Company"), a leading cannabis company focused on processing, sales, organoleptic testing and analytical testing, is pleased to provide the Company's shareholders with a corporate update from Michael Forbes, Director and Chief Executive Officer of Adastra:
- CNW Group
Adastra Holdings Reports First Quarter Results
Adastra Holdings Ltd. (CSE: XTRX) (FRA: D2EP) ("Adastra" or the "Company") is pleased to announce that it has filed its consolidated financial statements and related management discussion and analysis for the three months ended March 31, 2022, both of which are available at www.sedar.com.
